Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCGX9U)

Drug Name
PHA-665752 Drug Info
Synonyms
PHA-665752; 477575-56-7; PHA 665752; PHA665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate
Cross-matching ID
PubChem CID
10461815
ChEBI ID
CHEMBL90197
CAS Number
CAS 477575-56-7
TTD Drug ID
D00TBD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.65 0.00e+0 19/20 (95%) MSMO1;NSDHL;SQLE;...
Terpenoid backbone biosynthesis 2.14 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
Mineral absorption 2.04 0.00e+0 48/60 (80%) HMOX1;MT1X;HEPH;...
Fructose and mannose metabolism 2.02 4.12e-3 30/33 (90.91%) ALDOC;PFKFB3;PFKP;...
Pentose phosphate pathway 1.98 3.30e-3 25/30 (83.33%) ALDOC;PFKP;TKT;...
Biosynthesis of unsaturated fatty acids 1.96 2.75e-3 21/27 (77.78%) SCD;FADS1;ELOVL6;...
Synthesis and degradation of ketone bodies 1.95 4.71e-3 9/10 (90%) HMGCS1;ACAT2
Glycolysis / Gluconeogenesis 1.84 1.24e-2 56/67 (83.58%) ENO2;ALDOC;PFKP;...
PPAR signaling pathway 1.71 4.67e-2 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Thermogenesis -1.68 4.45e-2 173/232 (74.57%) ATP5F1A;COX16;COX5A;...
Leishmaniasis -1.69 4.69e-2 67/77 (87.01%) FOS;MARCKSL1;ITGB1;...
Intestinal immune network for IgA production -1.70 4.57e-2 38/48 (79.17%) HLA-DOA;CXCL12;TGFB1;...
Ribosome -1.72 3.85e-2 113/158 (71.52%) RPL27A;MRPL19;RPL41;...
Diabetic cardiomyopathy -1.72 4.23e-2 162/203 (79.8%) ATP5F1A;PPP1CA;GSR;...
Staphylococcus aureus infection -1.78 2.77e-2 72/95 (75.79%) DEFB1;FCGR2B;KRT18;...
Oxidative phosphorylation -1.81 1.87e-2 93/133 (69.92%) ATP5F1A;ATP6V1B1;ATP6V1G1;...
Autoimmune thyroid disease -1.85 1.25e-2 46/53 (86.79%) HLA-DRB1;HLA-DPA1;HLA-DQB1;...
Platelet activation -1.95 2.08e-3 106/124 (85.48%) ARHGAP35;F2R;PIK3CG;...
Systemic lupus erythematosus -1.99 0.00e+0 45/135 (33.33%) FCGR3B;HLA-DRB1;FCGR2A;...
Graft-versus-host disease -2.05 0.00e+0 32/42 (76.19%) HLA-DOA;KLRD1;HLA-DRB1;...
Asthma -2.08 0.00e+0 25/31 (80.65%) CCL11;PRG2;HLA-DOA;...
Allograft rejection -2.12 0.00e+0 32/38 (84.21%) HLA-DRB1;HLA-DPA1;HLA-DQB1;...
Type I diabetes mellitus -2.18 0.00e+0 38/43 (88.37%) PTPRN2;HLA-DRB1;CPE;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H